Oncology Anti-Cancer Drugs-United States Market Status and Trend Report 2013-2023
Report Summary
Oncology Anti-Cancer Drugs-United States Market Status and Trend Report 2013-2023 offers a comprehensive analysis on Oncology Anti-Cancer Drugs industry, standing on the readers? perspective, delivering detailed market data and penetrating insights. No matter the client is industry insider, potential entrant or investor, the report will provides useful data and information. Key questions answered by this report include:
Whole United States and Regional Market Size of Oncology Anti-Cancer Drugs 2013-2017, and development forecast 2018-2023
Main market players of Oncology Anti-Cancer Drugs in United States, with company and product introduction, position in the Oncology Anti-Cancer Drugs market
Market status and development trend of Oncology Anti-Cancer Drugs by types and applications
Cost and profit status of Oncology Anti-Cancer Drugs, and marketing status
Market growth drivers and challenges
The report segments the United States Oncology Anti-Cancer Drugs market as:
United States Oncology Anti-Cancer Drugs Market: Regional Segment Analysis (Regional Consumption Volume, Consumption Volume, Revenue and Growth Rate 2013-2023):
New England
The Middle Atlantic
The Midwest
The West
The South
Southwest
United States Oncology Anti-Cancer Drugs Market: Product Type Segment Analysis (Consumption Volume, Average Price, Revenue, Market Share and Trend 2013-2023):
Chemotherapy
Targeted Therapy
Immunotherapy (Biologic Therapy)
Hormonal Therapy
Others
United States Oncology Anti-Cancer Drugs Market: Application Segment Analysis (Consumption Volume and Market Share 2013-2023; Downstream Customers and Market Analysis)
Blood Cancer (Leukaemia)
Breast Cancer
Gastrointestinal Cancer
Respiratory/Lung Cancer
Skin Cancer
Other Cancers
United States Oncology Anti-Cancer Drugs Market: Players Segment Analysis (Company and Product introduction, Oncology Anti-Cancer Drugs Sales Volume, Revenue, Price and Gross Margin):
Amgen
AstraZeneca
Roche Diagnostics
GlaxoSmithKline
Merck
Novartis
AbbVie
Sanofi
EIMC United Pharmaceuticals
Actavis
In a word, the report provides detailed statistics and analysis on the state of the industry; and is a valuable source of guidance and direction for companies and individuals interested in the market.
Oncology Anti-Cancer Drugs-United States Market Status and Trend Report 2013-2023 offers a comprehensive analysis on Oncology Anti-Cancer Drugs industry, standing on the readers? perspective, delivering detailed market data and penetrating insights. No matter the client is industry insider, potential entrant or investor, the report will provides useful data and information. Key questions answered by this report include:
Whole United States and Regional Market Size of Oncology Anti-Cancer Drugs 2013-2017, and development forecast 2018-2023
Main market players of Oncology Anti-Cancer Drugs in United States, with company and product introduction, position in the Oncology Anti-Cancer Drugs market
Market status and development trend of Oncology Anti-Cancer Drugs by types and applications
Cost and profit status of Oncology Anti-Cancer Drugs, and marketing status
Market growth drivers and challenges
The report segments the United States Oncology Anti-Cancer Drugs market as:
United States Oncology Anti-Cancer Drugs Market: Regional Segment Analysis (Regional Consumption Volume, Consumption Volume, Revenue and Growth Rate 2013-2023):
New England
The Middle Atlantic
The Midwest
The West
The South
Southwest
United States Oncology Anti-Cancer Drugs Market: Product Type Segment Analysis (Consumption Volume, Average Price, Revenue, Market Share and Trend 2013-2023):
Chemotherapy
Targeted Therapy
Immunotherapy (Biologic Therapy)
Hormonal Therapy
Others
United States Oncology Anti-Cancer Drugs Market: Application Segment Analysis (Consumption Volume and Market Share 2013-2023; Downstream Customers and Market Analysis)
Blood Cancer (Leukaemia)
Breast Cancer
Gastrointestinal Cancer
Respiratory/Lung Cancer
Skin Cancer
Other Cancers
United States Oncology Anti-Cancer Drugs Market: Players Segment Analysis (Company and Product introduction, Oncology Anti-Cancer Drugs Sales Volume, Revenue, Price and Gross Margin):
Amgen
AstraZeneca
Roche Diagnostics
GlaxoSmithKline
Merck
Novartis
AbbVie
Sanofi
EIMC United Pharmaceuticals
Actavis
In a word, the report provides detailed statistics and analysis on the state of the industry; and is a valuable source of guidance and direction for companies and individuals interested in the market.
CHAPTER 1 OVERVIEW OF ONCOLOGY ANTI-CANCER DRUGS
1.1 Definition of Oncology Anti-Cancer Drugs in This Report
1.2 Commercial Types of Oncology Anti-Cancer Drugs
1.2.1 Chemotherapy
1.2.2 Targeted Therapy
1.2.3 Immunotherapy (Biologic Therapy)
1.2.4 Hormonal Therapy
1.2.5 Others
1.3 Downstream Application of Oncology Anti-Cancer Drugs
1.3.1 Blood Cancer (Leukaemia)
1.3.2 Breast Cancer
1.3.3 Gastrointestinal Cancer
1.3.4 Respiratory/Lung Cancer
1.3.5 Skin Cancer
1.3.6 Other Cancers
1.4 Development History of Oncology Anti-Cancer Drugs
1.5 Market Status and Trend of Oncology Anti-Cancer Drugs 2013-2023
1.5.1 United States Oncology Anti-Cancer Drugs Market Status and Trend 2013-2023
1.5.2 Regional Oncology Anti-Cancer Drugs Market Status and Trend 2013-2023
CHAPTER 2 UNITED STATES MARKET STATUS AND FORECAST BY REGIONS
2.1 Market Status of Oncology Anti-Cancer Drugs in United States 2013-2017
2.2 Consumption Market of Oncology Anti-Cancer Drugs in United States by Regions
2.2.1 Consumption Volume of Oncology Anti-Cancer Drugs in United States by Regions
2.2.2 Revenue of Oncology Anti-Cancer Drugs in United States by Regions
2.3 Market Analysis of Oncology Anti-Cancer Drugs in United States by Regions
2.3.1 Market Analysis of Oncology Anti-Cancer Drugs in New England 2013-2017
2.3.2 Market Analysis of Oncology Anti-Cancer Drugs in The Middle Atlantic 2013-2017
2.3.3 Market Analysis of Oncology Anti-Cancer Drugs in The Midwest 2013-2017
2.3.4 Market Analysis of Oncology Anti-Cancer Drugs in The West 2013-2017
2.3.5 Market Analysis of Oncology Anti-Cancer Drugs in The South 2013-2017
2.3.6 Market Analysis of Oncology Anti-Cancer Drugs in Southwest 2013-2017
2.4 Market Development Forecast of Oncology Anti-Cancer Drugs in United States 2018-2023
2.4.1 Market Development Forecast of Oncology Anti-Cancer Drugs in United States 2018-2023
2.4.2 Market Development Forecast of Oncology Anti-Cancer Drugs by Regions 2018-2023
CHAPTER 3 UNITED STATES MARKET STATUS AND FORECAST BY TYPES
3.1 Whole United States Market Status by Types
3.1.1 Consumption Volume of Oncology Anti-Cancer Drugs in United States by Types
3.1.2 Revenue of Oncology Anti-Cancer Drugs in United States by Types
3.2 United States Market Status by Types in Major Countries
3.2.1 Market Status by Types in New England
3.2.2 Market Status by Types in The Middle Atlantic
3.2.3 Market Status by Types in The Midwest
3.2.4 Market Status by Types in The West
3.2.5 Market Status by Types in The South
3.2.6 Market Status by Types in Southwest
3.3 Market Forecast of Oncology Anti-Cancer Drugs in United States by Types
CHAPTER 4 UNITED STATES MARKET STATUS AND FORECAST BY DOWNSTREAM INDUSTRY
4.1 Demand Volume of Oncology Anti-Cancer Drugs in United States by Downstream Industry
4.2 Demand Volume of Oncology Anti-Cancer Drugs by Downstream Industry in Major Countries
4.2.1 Demand Volume of Oncology Anti-Cancer Drugs by Downstream Industry in New England
4.2.2 Demand Volume of Oncology Anti-Cancer Drugs by Downstream Industry in The Middle Atlantic
4.2.3 Demand Volume of Oncology Anti-Cancer Drugs by Downstream Industry in The Midwest
4.2.4 Demand Volume of Oncology Anti-Cancer Drugs by Downstream Industry in The West
4.2.5 Demand Volume of Oncology Anti-Cancer Drugs by Downstream Industry in The South
4.2.6 Demand Volume of Oncology Anti-Cancer Drugs by Downstream Industry in Southwest
4.3 Market Forecast of Oncology Anti-Cancer Drugs in United States by Downstream Industry
CHAPTER 5 MARKET DRIVING FACTOR ANALYSIS OF ONCOLOGY ANTI-CANCER DRUGS
5.1 United States Economy Situation and Trend Overview
5.2 Oncology Anti-Cancer Drugs Downstream Industry Situation and Trend Overview
CHAPTER 6 ONCOLOGY ANTI-CANCER DRUGS MARKET COMPETITION STATUS BY MAJOR PLAYERS IN UNITED STATES
6.1 Sales Volume of Oncology Anti-Cancer Drugs in United States by Major Players
6.2 Revenue of Oncology Anti-Cancer Drugs in United States by Major Players
6.3 Basic Information of Oncology Anti-Cancer Drugs by Major Players
6.3.1 Headquarters Location and Established Time of Oncology Anti-Cancer Drugs Major Players
6.3.2 Employees and Revenue Level of Oncology Anti-Cancer Drugs Major Players
6.4 Market Competition News and Trend
6.4.1 Merger, Consolidation or Acquisition News
6.4.2 Investment or Disinvestment News
6.4.3 New Product Development and Launch
CHAPTER 7 ONCOLOGY ANTI-CANCER DRUGS MAJOR MANUFACTURERS INTRODUCTION AND MARKET DATA
7.1 Amgen
7.1.1 Company profile
7.1.2 Representative Oncology Anti-Cancer Drugs Product
7.1.3 Oncology Anti-Cancer Drugs Sales, Revenue, Price and Gross Margin of Amgen
7.2 AstraZeneca
7.2.1 Company profile
7.2.2 Representative Oncology Anti-Cancer Drugs Product
7.2.3 Oncology Anti-Cancer Drugs Sales, Revenue, Price and Gross Margin of AstraZeneca
7.3 Roche Diagnostics
7.3.1 Company profile
7.3.2 Representative Oncology Anti-Cancer Drugs Product
7.3.3 Oncology Anti-Cancer Drugs Sales, Revenue, Price and Gross Margin of Roche Diagnostics
7.4 GlaxoSmithKline
7.4.1 Company profile
7.4.2 Representative Oncology Anti-Cancer Drugs Product
7.4.3 Oncology Anti-Cancer Drugs Sales, Revenue, Price and Gross Margin of GlaxoSmithKline
7.5 Merck
7.5.1 Company profile
7.5.2 Representative Oncology Anti-Cancer Drugs Product
7.5.3 Oncology Anti-Cancer Drugs Sales, Revenue, Price and Gross Margin of Merck
7.6 Novartis
7.6.1 Company profile
7.6.2 Representative Oncology Anti-Cancer Drugs Product
7.6.3 Oncology Anti-Cancer Drugs Sales, Revenue, Price and Gross Margin of Novartis
7.7 AbbVie
7.7.1 Company profile
7.7.2 Representative Oncology Anti-Cancer Drugs Product
7.7.3 Oncology Anti-Cancer Drugs Sales, Revenue, Price and Gross Margin of AbbVie
7.8 Sanofi
7.8.1 Company profile
7.8.2 Representative Oncology Anti-Cancer Drugs Product
7.8.3 Oncology Anti-Cancer Drugs Sales, Revenue, Price and Gross Margin of Sanofi
7.9 EIMC United Pharmaceuticals
7.9.1 Company profile
7.9.2 Representative Oncology Anti-Cancer Drugs Product
7.9.3 Oncology Anti-Cancer Drugs Sales, Revenue, Price and Gross Margin of EIMC United Pharmaceuticals
7.10 Actavis
7.10.1 Company profile
7.10.2 Representative Oncology Anti-Cancer Drugs Product
7.10.3 Oncology Anti-Cancer Drugs Sales, Revenue, Price and Gross Margin of Actavis
CHAPTER 8 UPSTREAM AND DOWNSTREAM MARKET ANALYSIS OF ONCOLOGY ANTI-CANCER DRUGS
8.1 Industry Chain of Oncology Anti-Cancer Drugs
8.2 Upstream Market and Representative Companies Analysis
8.3 Downstream Market and Representative Companies Analysis
CHAPTER 9 COST AND GROSS MARGIN ANALYSIS OF ONCOLOGY ANTI-CANCER DRUGS
9.1 Cost Structure Analysis of Oncology Anti-Cancer Drugs
9.2 Raw Materials Cost Analysis of Oncology Anti-Cancer Drugs
9.3 Labor Cost Analysis of Oncology Anti-Cancer Drugs
9.4 Manufacturing Expenses Analysis of Oncology Anti-Cancer Drugs
CHAPTER 10 MARKETING STATUS ANALYSIS OF ONCOLOGY ANTI-CANCER DRUGS
10.1 Marketing Channel
10.1.1 Direct Marketing
10.1.2 Indirect Marketing
10.1.3 Marketing Channel Development Trend
10.2 Market Positioning
10.2.1 Pricing Strategy
10.2.2 Brand Strategy
10.2.3 Target Client
10.3 Distributors/Traders List
CHAPTER 11 REPORT CONCLUSION
CHAPTER 12 RESEARCH METHODOLOGY AND REFERENCE
12.1 Methodology/Research Approach
12.1.1 Research Programs/Design
12.1.2 Market Size Estimation
12.1.3 Market Breakdown and Data Triangulation
12.2 Data Source
12.2.1 Secondary Sources
12.2.2 Primary Sources
12.3 Reference
1.1 Definition of Oncology Anti-Cancer Drugs in This Report
1.2 Commercial Types of Oncology Anti-Cancer Drugs
1.2.1 Chemotherapy
1.2.2 Targeted Therapy
1.2.3 Immunotherapy (Biologic Therapy)
1.2.4 Hormonal Therapy
1.2.5 Others
1.3 Downstream Application of Oncology Anti-Cancer Drugs
1.3.1 Blood Cancer (Leukaemia)
1.3.2 Breast Cancer
1.3.3 Gastrointestinal Cancer
1.3.4 Respiratory/Lung Cancer
1.3.5 Skin Cancer
1.3.6 Other Cancers
1.4 Development History of Oncology Anti-Cancer Drugs
1.5 Market Status and Trend of Oncology Anti-Cancer Drugs 2013-2023
1.5.1 United States Oncology Anti-Cancer Drugs Market Status and Trend 2013-2023
1.5.2 Regional Oncology Anti-Cancer Drugs Market Status and Trend 2013-2023
CHAPTER 2 UNITED STATES MARKET STATUS AND FORECAST BY REGIONS
2.1 Market Status of Oncology Anti-Cancer Drugs in United States 2013-2017
2.2 Consumption Market of Oncology Anti-Cancer Drugs in United States by Regions
2.2.1 Consumption Volume of Oncology Anti-Cancer Drugs in United States by Regions
2.2.2 Revenue of Oncology Anti-Cancer Drugs in United States by Regions
2.3 Market Analysis of Oncology Anti-Cancer Drugs in United States by Regions
2.3.1 Market Analysis of Oncology Anti-Cancer Drugs in New England 2013-2017
2.3.2 Market Analysis of Oncology Anti-Cancer Drugs in The Middle Atlantic 2013-2017
2.3.3 Market Analysis of Oncology Anti-Cancer Drugs in The Midwest 2013-2017
2.3.4 Market Analysis of Oncology Anti-Cancer Drugs in The West 2013-2017
2.3.5 Market Analysis of Oncology Anti-Cancer Drugs in The South 2013-2017
2.3.6 Market Analysis of Oncology Anti-Cancer Drugs in Southwest 2013-2017
2.4 Market Development Forecast of Oncology Anti-Cancer Drugs in United States 2018-2023
2.4.1 Market Development Forecast of Oncology Anti-Cancer Drugs in United States 2018-2023
2.4.2 Market Development Forecast of Oncology Anti-Cancer Drugs by Regions 2018-2023
CHAPTER 3 UNITED STATES MARKET STATUS AND FORECAST BY TYPES
3.1 Whole United States Market Status by Types
3.1.1 Consumption Volume of Oncology Anti-Cancer Drugs in United States by Types
3.1.2 Revenue of Oncology Anti-Cancer Drugs in United States by Types
3.2 United States Market Status by Types in Major Countries
3.2.1 Market Status by Types in New England
3.2.2 Market Status by Types in The Middle Atlantic
3.2.3 Market Status by Types in The Midwest
3.2.4 Market Status by Types in The West
3.2.5 Market Status by Types in The South
3.2.6 Market Status by Types in Southwest
3.3 Market Forecast of Oncology Anti-Cancer Drugs in United States by Types
CHAPTER 4 UNITED STATES MARKET STATUS AND FORECAST BY DOWNSTREAM INDUSTRY
4.1 Demand Volume of Oncology Anti-Cancer Drugs in United States by Downstream Industry
4.2 Demand Volume of Oncology Anti-Cancer Drugs by Downstream Industry in Major Countries
4.2.1 Demand Volume of Oncology Anti-Cancer Drugs by Downstream Industry in New England
4.2.2 Demand Volume of Oncology Anti-Cancer Drugs by Downstream Industry in The Middle Atlantic
4.2.3 Demand Volume of Oncology Anti-Cancer Drugs by Downstream Industry in The Midwest
4.2.4 Demand Volume of Oncology Anti-Cancer Drugs by Downstream Industry in The West
4.2.5 Demand Volume of Oncology Anti-Cancer Drugs by Downstream Industry in The South
4.2.6 Demand Volume of Oncology Anti-Cancer Drugs by Downstream Industry in Southwest
4.3 Market Forecast of Oncology Anti-Cancer Drugs in United States by Downstream Industry
CHAPTER 5 MARKET DRIVING FACTOR ANALYSIS OF ONCOLOGY ANTI-CANCER DRUGS
5.1 United States Economy Situation and Trend Overview
5.2 Oncology Anti-Cancer Drugs Downstream Industry Situation and Trend Overview
CHAPTER 6 ONCOLOGY ANTI-CANCER DRUGS MARKET COMPETITION STATUS BY MAJOR PLAYERS IN UNITED STATES
6.1 Sales Volume of Oncology Anti-Cancer Drugs in United States by Major Players
6.2 Revenue of Oncology Anti-Cancer Drugs in United States by Major Players
6.3 Basic Information of Oncology Anti-Cancer Drugs by Major Players
6.3.1 Headquarters Location and Established Time of Oncology Anti-Cancer Drugs Major Players
6.3.2 Employees and Revenue Level of Oncology Anti-Cancer Drugs Major Players
6.4 Market Competition News and Trend
6.4.1 Merger, Consolidation or Acquisition News
6.4.2 Investment or Disinvestment News
6.4.3 New Product Development and Launch
CHAPTER 7 ONCOLOGY ANTI-CANCER DRUGS MAJOR MANUFACTURERS INTRODUCTION AND MARKET DATA
7.1 Amgen
7.1.1 Company profile
7.1.2 Representative Oncology Anti-Cancer Drugs Product
7.1.3 Oncology Anti-Cancer Drugs Sales, Revenue, Price and Gross Margin of Amgen
7.2 AstraZeneca
7.2.1 Company profile
7.2.2 Representative Oncology Anti-Cancer Drugs Product
7.2.3 Oncology Anti-Cancer Drugs Sales, Revenue, Price and Gross Margin of AstraZeneca
7.3 Roche Diagnostics
7.3.1 Company profile
7.3.2 Representative Oncology Anti-Cancer Drugs Product
7.3.3 Oncology Anti-Cancer Drugs Sales, Revenue, Price and Gross Margin of Roche Diagnostics
7.4 GlaxoSmithKline
7.4.1 Company profile
7.4.2 Representative Oncology Anti-Cancer Drugs Product
7.4.3 Oncology Anti-Cancer Drugs Sales, Revenue, Price and Gross Margin of GlaxoSmithKline
7.5 Merck
7.5.1 Company profile
7.5.2 Representative Oncology Anti-Cancer Drugs Product
7.5.3 Oncology Anti-Cancer Drugs Sales, Revenue, Price and Gross Margin of Merck
7.6 Novartis
7.6.1 Company profile
7.6.2 Representative Oncology Anti-Cancer Drugs Product
7.6.3 Oncology Anti-Cancer Drugs Sales, Revenue, Price and Gross Margin of Novartis
7.7 AbbVie
7.7.1 Company profile
7.7.2 Representative Oncology Anti-Cancer Drugs Product
7.7.3 Oncology Anti-Cancer Drugs Sales, Revenue, Price and Gross Margin of AbbVie
7.8 Sanofi
7.8.1 Company profile
7.8.2 Representative Oncology Anti-Cancer Drugs Product
7.8.3 Oncology Anti-Cancer Drugs Sales, Revenue, Price and Gross Margin of Sanofi
7.9 EIMC United Pharmaceuticals
7.9.1 Company profile
7.9.2 Representative Oncology Anti-Cancer Drugs Product
7.9.3 Oncology Anti-Cancer Drugs Sales, Revenue, Price and Gross Margin of EIMC United Pharmaceuticals
7.10 Actavis
7.10.1 Company profile
7.10.2 Representative Oncology Anti-Cancer Drugs Product
7.10.3 Oncology Anti-Cancer Drugs Sales, Revenue, Price and Gross Margin of Actavis
CHAPTER 8 UPSTREAM AND DOWNSTREAM MARKET ANALYSIS OF ONCOLOGY ANTI-CANCER DRUGS
8.1 Industry Chain of Oncology Anti-Cancer Drugs
8.2 Upstream Market and Representative Companies Analysis
8.3 Downstream Market and Representative Companies Analysis
CHAPTER 9 COST AND GROSS MARGIN ANALYSIS OF ONCOLOGY ANTI-CANCER DRUGS
9.1 Cost Structure Analysis of Oncology Anti-Cancer Drugs
9.2 Raw Materials Cost Analysis of Oncology Anti-Cancer Drugs
9.3 Labor Cost Analysis of Oncology Anti-Cancer Drugs
9.4 Manufacturing Expenses Analysis of Oncology Anti-Cancer Drugs
CHAPTER 10 MARKETING STATUS ANALYSIS OF ONCOLOGY ANTI-CANCER DRUGS
10.1 Marketing Channel
10.1.1 Direct Marketing
10.1.2 Indirect Marketing
10.1.3 Marketing Channel Development Trend
10.2 Market Positioning
10.2.1 Pricing Strategy
10.2.2 Brand Strategy
10.2.3 Target Client
10.3 Distributors/Traders List
CHAPTER 11 REPORT CONCLUSION
CHAPTER 12 RESEARCH METHODOLOGY AND REFERENCE
12.1 Methodology/Research Approach
12.1.1 Research Programs/Design
12.1.2 Market Size Estimation
12.1.3 Market Breakdown and Data Triangulation
12.2 Data Source
12.2.1 Secondary Sources
12.2.2 Primary Sources
12.3 Reference
